Sunday, October 08, 2017 11:27:42 PM
This seems to be a good potential for a stock to go long - but I have some questions..Hopefully someone can shed some light.
1. From recent news, the company indicated that the recent stock issuance is to allow the Company to fund the "initiation of its Phase 3 clinical program" of RP-G28 for the treatment of lactose intolerance, expected to begin in the first half of 2018. --->The word "initiation" somehow really bothers me as it sounds like, there may be more coming. Can someone shed somelight on this?
2. Potential of >$1.2Billions of prescription market. Can someone translate tha to sales or perhaps potential sp?
3. Timeline of completion of P3 Trial?
Thanks
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM